220 related articles for article (PubMed ID: 14585803)
1. Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram.
Soares AC; Souza DG; Pinho V; Vieira AT; Barsante MM; Nicoli JR; Teixeira M
Br J Pharmacol; 2003 Nov; 140(5):855-62. PubMed ID: 14585803
[TBL] [Abstract][Full Text] [Related]
2. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Souza DG; Cassali GD; Poole S; Teixeira MM
Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
[TBL] [Abstract][Full Text] [Related]
3. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
Blease K; Burke-Gaffney A; Hellewell PG
Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
[TBL] [Abstract][Full Text] [Related]
4. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
5. Effect of PDE4 inhibitors on zymosan-induced IL-8 release from human neutrophils: synergism with prostanoids and salbutamol.
Au BT; Teixeira MM; Collins PD; Williams TJ
Br J Pharmacol; 1998 Mar; 123(6):1260-6. PubMed ID: 9559913
[TBL] [Abstract][Full Text] [Related]
6. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Ikemura T; Schwarze J; Makela M; Kanehiro A; Joetham A; Ohmori K; Gelfand EW
J Pharmacol Exp Ther; 2000 Aug; 294(2):701-6. PubMed ID: 10900250
[TBL] [Abstract][Full Text] [Related]
7. Action of a Novel PDE4 inhibitor ZL-n-91 on lipopolysaccharide-induced acute lung injury.
Tang HF; Lu JJ; Tang JF; Zheng X; Liang YQ; Wang XF; Wang YJ; Mao LG; Chen JQ
Int Immunopharmacol; 2010 Apr; 10(4):406-11. PubMed ID: 20074667
[TBL] [Abstract][Full Text] [Related]
8. Suppression of acute lung injury in mice by an inhibitor of phosphodiesterase type 4.
Miotla JM; Teixeira MM; Hellewell PG
Am J Respir Cell Mol Biol; 1998 Mar; 18(3):411-20. PubMed ID: 9490659
[TBL] [Abstract][Full Text] [Related]
9. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
11. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
12. Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation.
Ariga M; Neitzert B; Nakae S; Mottin G; Bertrand C; Pruniaux MP; Jin SL; Conti M
J Immunol; 2004 Dec; 173(12):7531-8. PubMed ID: 15585880
[TBL] [Abstract][Full Text] [Related]
13. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
Harada D; Tsukumo Y; Takashima Y; Manabe H
Eur J Pharmacol; 2006 Feb; 532(1-2):128-37. PubMed ID: 16442096
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
15. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
[TBL] [Abstract][Full Text] [Related]
16. Thalidomide treatment modulates macrophage pro-inflammatory function and cytokine levels in Klebsiella pneumoniae B5055 induced pneumonia in BALB/c mice.
Kumar V; Harjai K; Chhibber S
Int Immunopharmacol; 2010 Jul; 10(7):777-83. PubMed ID: 20399910
[TBL] [Abstract][Full Text] [Related]
17. Discriminative stimulus effects of the type-4 phosphodiesterase inhibitor rolipram in rats.
Makhay MM; Houslay MD; O'Donnell JM
Psychopharmacology (Berl); 2001 Nov; 158(3):297-304. PubMed ID: 11713620
[TBL] [Abstract][Full Text] [Related]
18. Lung-specific transgenic expression of KC enhances resistance to Klebsiella pneumoniae in mice.
Tsai WC; Strieter RM; Wilkowski JM; Bucknell KA; Burdick MD; Lira SA; Standiford TJ
J Immunol; 1998 Sep; 161(5):2435-40. PubMed ID: 9725241
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
[TBL] [Abstract][Full Text] [Related]
20. Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor.
Aoki M; Fukunaga M; Sugimoto T; Hirano Y; Kobayashi M; Honda K; Yamada T
J Pharmacol Exp Ther; 2001 Sep; 298(3):1142-9. PubMed ID: 11504812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
